Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial
Public ClinicalTrials.gov record NCT01593228. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
International, Multi-Center, Open-label, Treatment Extension Study of Iniparib as Monotherapy or in Combination Chemotherapeutic Regimens in Cancer Patients Who Have Derived Clinical Benefit From Iniparib Following Completion of a Phase 1, 2 or 3 Parental Study
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to assess the safety and tolerability of iniparib administered as monotherapy or in combination regimens in patients previously treated with iniparib in a clinical study and who have derived clinical benefit after completion of the parental study's objectives.
Study identification
- NCT ID
- NCT01593228
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 37 participants
Conditions and interventions
Conditions
Interventions
- Iniparib (SAR240550/BSI-201) Drug
- Carboplatin Drug
- Doxorubicin HCL liposome injection Drug
- Gemcitabine Drug
- Irinotecan Drug
- Paclitaxel Drug
- Topotecan Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 2012 (Type not available)
- Primary completion
- Sep 2016 (Actual)
- Completion
- Sep 2016 (Actual)
- Last update posted
- Sep 19, 2017
2012 – 2016
United States locations
- U.S. sites
- 29
- U.S. states
- 23
- U.S. cities
- 28
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigational Site Number 840013 | Birmingham | Alabama | 35205 | — |
| Investigational Site Number 840033 | Santa Maria | California | 93454-8903 | — |
| Investigational Site Number 840046 | Vallejo | California | 94589 | — |
| Investigational Site Number 840008 | Denver | Colorado | 80218 | — |
| Investigational Site Number 840027 | Jacksonville | Florida | 32256 | — |
| Investigational Site Number 840063 | Augusta | Georgia | 30912 | — |
| Investigational Site Number 840055 | Tucker | Georgia | 30084 | — |
| Investigational Site Number 840039 | Maywood | Illinois | 60153 | — |
| Investigational Site Number 840012 | Indianapolis | Indiana | 46227 | — |
| Investigational Site Number 840025 | Sioux City | Iowa | 51105 | — |
| Investigational Site Number 840030 | Boston | Massachusetts | 02115 | — |
| Investigational Site Number 840001 | Detroit | Michigan | 48201 | — |
| Investigational Site Number 840006 | Minneapolis | Minnesota | 55407-3799 | — |
| Investigational Site Number 840002 | Jackson | Mississippi | 39202 | — |
| Investigational Site Number 840059 | St Louis | Missouri | 63110 | — |
| Investigational Site Number 840004 | St Louis | Missouri | 63141 | — |
| Investigational Site Number 840022 | Las Vegas | Nevada | 89169 | — |
| Investigational Site Number 840017 | Voorhees Township | New Jersey | 08043 | — |
| Investigational Site Number 840010 | Albany | New York | 12206 | — |
| Investigational Site Number 840015 | Charlotte | North Carolina | — | — |
| Investigational Site Number 840060 | Cincinnati | Ohio | — | — |
| Investigational Site Number 840043 | Cleveland | Ohio | 44106 | — |
| Investigational Site Number 840021 | Pittsburgh | Pennsylvania | 15213 | — |
| Investigational Site Number 840028 | Memphis | Tennessee | 38120-2146 | — |
| Investigational Site Number 840007 | Austin | Texas | 78731 | — |
| Investigational Site Number 840003 | El Paso | Texas | 79915 | — |
| Investigational Site Number 840019 | Plano | Texas | 75075 | — |
| Investigational Site Number 840005 | Norfolk | Virginia | 23502 | — |
| Investigational Site Number 840009 | Vancouver | Washington | 98684 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01593228, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 19, 2017 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01593228 live on ClinicalTrials.gov.